Current aspects of invasive candidiasis and aspergillosis in adult intensive care patients

Mycoses

Volumn 54, Issue 5, 2011, Pages 420-433

  Glockner A ^a   Karthaus, M ^b  

^a BDH Klinik Greifswald GmbH   (Germany)

^b Klinikum Neuperlach   (Germany)

Author keywords

Candidaemia; Echinocandin; Intensive care; Invasive aspergillosis; Invasive candidiasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIBIOTIC AGENT; CASPOFUNGIN; CORTICOSTEROID; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE;

ABDOMINAL ABSCESS; ABDOMINAL SURGERY; ACUTE HEMORRHAGIC PANCREATITIS; ACUTE KIDNEY FAILURE; ANASTOMOSIS LEAKAGE; ANTIBIOTIC THERAPY; ANTIFUNGAL SUSCEPTIBILITY; ANTIMICROBIAL THERAPY; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CANCER SURGERY; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CENTRAL VENOUS CATHETER; CRITICALLY ILL PATIENT; DIABETES MELLITUS; DIGESTIVE SYSTEM PERFORATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; FUNGUS ISOLATION; HEMATOLOGIC MALIGNANCY; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; HYPOKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTENSIVE CARE; INTENSIVE CARE UNIT; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LIVER TUMOR; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PARENTERAL NUTRITION; PERSISTENT INFECTION; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SPECIES DISTRIBUTION; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; CANDIDIASIS, INVASIVE; HUMANS; INTENSIVE CARE; INVASIVE PULMONARY ASPERGILLOSIS; SEPSIS; TREATMENT OUTCOME;

CANDIDA;

EID: 80052797604     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2010.01885.x     Document Type: Review

References (89)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
2. Engel C, Brunkhorst FM, Bone HG et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 2007; 33: 606-18.
3. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006; 27: 359-66.
4. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-9.
5. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
6. Bouza E, Muñoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 2008; 32(Suppl. 2): S87-91.
7. Guery BP, Arendrup MC, Auzinger G et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med 2009; 35: 55-62.
8. Marshall JC, Christou NV, Meakins JL. The gastrointestinal tract. The 'undrained abscess' of multiple organ failure. Ann Surg 1993; 218: 111-9.
9. Eggimann P, Francioli P, Bille J et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27: 1066-72.
10. Chow JK, Golan Y, Ruthazer R et al. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med 2008; 36: 1993-8.
11. Hoerauf A, Hammer S, Müller-Myhsok B, Rupprecht H. Intra-abdominal Candida infection during acute necrotizing pancreatitis has a high prevalence and is associated with increased mortality. Crit Care Med 1998; 26: 2010-5.
12. Pyrgos V, Ratanavanich K, Donegan N, Veis J, Walsh TJ, Shoham S. Candida bloodstream infections in hemodialysis recipients. Med Mycol 2008; 47: 463-7.
13. Blumberg HM, Jarvis WR, Soucie JM et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33: 177-86.
14. Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Hammond JM, Hendrix CW. The diagnostic value of fungal surveillance cultures in critically ill patients. Surg Infect (Larchmt) 2000; 1: 273-81.
15. Shorr AF, Gupta V, Sun X, Johannes RS, Spalding J, Tabak YP. Burden of early-onset candidemia: analysis of culture-positive bloodstream infections from a large U.S. database. Crit Care Med 2009; 37: 2519-26.
16. León C, Ruiz-Santana S, Saavedra P et al. Usefulness of the 'Candida score' for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009; 37: 1624-33.
17. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751-8.
18. León C, Ruiz-Santana S, Saavedra P et al. A bedside scoring system ('Candida score') for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34: 730-7.
19. Ostrosky-Zeichner L, Sable C, Sobel J et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26: 271-6.
20. Ostrosky-Zeichner L, Pappas PG, Shoham S et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses 2009; [Epub ahead of print].
21. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2, 500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005; 43: 5425-7.
22. Karthaus M, Fleckenstein D, Schaefer H, Nibler K, Schwarzkopf-Steinhauser G. Recent epidemiology trends of Candida infections in cancer and non-cancer patients. ICAAC 2008 (Abstract M-723).
23. Davis SL, Vazquez JA, McKinnon PS. Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients. Ann Pharmacother 2007; 41: 568-73.
24. Magill SS, Swoboda SM, Shields CE et al. The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial. Ann Surg 2009; 249: 657-65.
25. Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009; 115: 4745-52.
26. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.
27. Gloeckner A, Abel P, Zimmermann K. Mycological findings upon admission to a non-surgical ICU - a prospective study. ICC 2005 (Abstract C6.1).
28. Dimopoulos G, Ntziora F, Rachiotis G, Armaganidis A, Falagas ME. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg 2008; 106: 523-9.
29. Fernandez J, Erstad BL, Petty W, Nix DE. Time to positive culture and identification for Candida blood stream infections. Diagn Microbiol Infect Dis 2009; 64: 402-7.
30. Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of antifungal timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother 2010; 54: 184-90.
31. Foster N, Symes C, Barton R, Hobson R. Rapid identification of Candida glabrata in Candida bloodstream infection. J Med Microbiol 2007; 56: 1639-43.
32. Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Multicenter clinical evaluation of the (1-3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-9.
33. McMullan R, Metwally L, Coyle PV et al. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis 2008; 46: 890-6.
34. Bennett J. Is real-time polymerase chain reaction ready for real use in detecting candidemia? Clin Infect Dis 2008; 46: 897-8.
35. Kumar A, Skrobik I, Guzman J et al. The high mortality of Candida septic shock is explained by excessive delays in initiation of antifungal therapy. ICAAC 2007 (Abstract K-2174).
36. Kumar A, Ellis P, Arabi Y et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136: 1237-48.
37. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
38. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
39. Hope WW, Drusano GL, Moore CB et al. Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. Antimicrob Agents Chemother 2007; 51: 285-95.
40. Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
41. Schuster MG, Edwards JE Jr, Sobel JD et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008; 149: 83-90.
42. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
43. Herbrecht R, Flückiger U, Gachot B, Ribaud P, Thiebaut A, Cordonnier C. Antifungal therapy in leukemia patients: 2009 update of the ECIL 1 and ECIL 2 guidelines. 2009. URL [accessed on 29 March 2010].
44. Ullmann AJ, Sanz MA, Tramarin A et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006; 43: e29-38.
45. Böhme A, Ruhnke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients - recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009; 88: 97-110.
46. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
47. Glöckner A, Steinbach A, Vehreschild JJ, Cornely OA. Treatment of invasive candidiasis with echinocandins. Mycoses 2009; 52: 476-86.
48. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
49. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-27.
50. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93.
51. Phillips P, Shafran S, Garber G et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997; 16: 337-45.
52. Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221-8.
53. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007; 45: 1735-45.
54. Pfizer. Fachinformation (Summary of Product Characteristics), Ecalta (Anidulafungin). Berlin: Pfizer, 2009.
55. MSD. Fachinformation (Summary of Product Characteristics), Cancidas (Caspofungin). Haar: MSD, 2008.
56. Astellas. Fachinformation (Summary of Product Characteristics), Mycamine (Micafungin). Munich: Astellas, 2008.
57. Muraki Y, Iwamoto T, Kagawa Y et al. The impact of total bilirubin on plasma micafungin levels in living-donor liver transplantation recipients with severe liver dysfunction. Biol Pharm Bull 2009; 32: 750-4.
58. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007; 27: 369-88.
59. Nguyen TH, Hoppe-Tichy T, Geiss HK et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother 2007; 60: 100-6.
60. EMEA. Mycamine Public Assessment Report. H-734-en6. 2009. URL [accessed on 29 March 2010].
61. FDA. Prescribing Information for Mycamine. 2005. URL [accessed on 29 March 2010].
62. Pappas G, Ierodiakonou V, Falagas ME. Lost in translation: differences in antimicrobial indication approval policies between the United States and Europe. Clin Ther 2009; 31: 1595-603.
63. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331: 1325-30.
64. Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435-42.
65. Lopes JA, Fernandes P, Jorge S et al. Acute kidney injury in intensive care unit patients: a comparison between the RIFLE and the Acute Kidney Injury Network classifications. Crit Care 2008; 12: R110.
66. Eichhorn ME, Wolf H, Küchenhoff H, Joka M, Jauch KW, Hartl WH. Secular trends in severe renal failure associated with the use of new antimicrobial agents in critically ill surgical patients. Eur J Clin Microbiol Infect Dis 2007; 26: 395-402.
67. Hachem R, Hanna H, Kontoyiannis D et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008; 112: 2493-9.
68. Bassetti M, Righi E, Costa A et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006; 6: 21.
69. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006; 34: 857-63.
70. Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother 2008; 52: 2263-5.
71. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008; 56: 126-9.
72. Davis S, Kouza A, Wiegand T, Vazquez J. Conversion of intravenous echinocandins to oral azoles for invasive candidiasis: impact on outcomes and resource utilisation. ECCMID 2008 (Abstract O458).
73. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1-45.
74. Jacobson MJ, Piper KE, Nguyen G, Steckelberg JM, Patel R. In vitro activity of anidulafungin against Candida albicans biofilms. Antimicrob Agents Chemother 2008; 52: 2242-3.
75. Kuhn DM, George T, Chandra J et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773-80.
76. Patel GP, Simon D, Scheetz M, Crank CW, Lodise T, Patel N. The effect of time to antifungal therapy on mortality in candidemia associated septic shock. Am J Ther 2009; 16: 508-11.
77. Vardakas KZ, Samonis G, Michalopoulos A, Soteriades ES, Falagas ME. Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. Crit Care Med 2006; 34: 1216-24.
78. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006; 57: 628-38.
79. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 2005; 33: 1928-35.
80. Senn L, Eggimann P, Ksontini R et al. Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. Intensive Care Med 2009; 35: 903-8.
81. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28: 1708-17.
82. Pelz RK, Hendrix CW, Swoboda SM et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233: 542-8.
83. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004; 170: 621-5.
84. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45: 205-16.
85. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-9.
86. Maertens J, Theunissen K, Lodewyck T, Lagrou K, Van Eldere J. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses 2007; 50(Suppl. 1): 2-17.
87. Meersseman W, Lagrou K, Maertens J et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008; 177: 27-34.
88. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
89. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.